Compare UTF & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | COGT |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | N/A | 2018 |
| Metric | UTF | COGT |
|---|---|---|
| Price | $23.76 | $39.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $28.08 |
| AVG Volume (30 Days) | 171.7K | ★ 3.5M |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 7.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $138,636,669.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.16 | ★ N/A |
| Revenue Growth | ★ 19.80 | N/A |
| 52 Week Low | $22.05 | $3.72 |
| 52 Week High | $26.53 | $43.73 |
| Indicator | UTF | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 72.28 |
| Support Level | $23.47 | $37.86 |
| Resistance Level | $24.14 | $43.73 |
| Average True Range (ATR) | 0.26 | 2.04 |
| MACD | -0.04 | -0.67 |
| Stochastic Oscillator | 28.21 | 56.31 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.